News from entremed, inc

Jun 13, 2014, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other...

Jun 03, 2014, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed appoints Franklin C. Salisbury, Jr., President of NFCR, to Board of Directors

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other...

May 19, 2014, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Announces Poster Presentations At ASCO On ENMD-2076

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases,...

May 15, 2014, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Reports First Quarter 2014 Financial Results

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases,...

Mar 21, 2014, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Reports 2013 Fourth Quarter And Full Year Financial Results

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases,...

Jan 13, 2014, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today...

Nov 14, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Reports Third Quarter 2013 Financial Results

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

Oct 31, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

Oct 22, 2013, 13:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

Oct 21, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer

 EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

Aug 14, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Reports Second Quarter 2013 Financial Results

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

Jul 29, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials

EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

Jun 27, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA To Expand Clinical Trial For Advanced/Metastatic Sarcoma

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

May 15, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Reports First Quarter 2013 Financial Results

 EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31,...

May 06, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

May 03, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers,...

Apr 05, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Announces Changes to Board of Directors and CEO Appointment

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today...

Mar 21, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results...

Mar 01, 2013, 08:30 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed To Raise $10.7 Million In Registered Direct Offering

 EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today...

Jan 23, 2013, 07:00 ET
EntreMed logo. (PRNewsFoto/ENTREMED)

EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a single-center Phase 2 study entitled...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer